Characterization of a novel tumor-suppressor gene PLCδ1 at 3p22 in esophageal squamous cell carcinoma

Cancer Research

Volumn 67, Issue 22, 2007, Pages 10720-10726

  Fu, Li ^a   Qin, Yan Ru ^b   Xie, Dan ^c   Hu, Liang ^a   Kwong, Dora L ^a   Srivastava, Gopesh ^a   Sai, Wah Tsao ^a   Guan, Xin Yuan ^a,c  

^a UNIVERSITY OF HONG KONG   (Hong Kong)

^b THE FIRST AFFILIATED HOSPITAL OF ZHENGZHOU UNIVERSITY   (China)

^c SUN YAT SEN UNIVERSITY CANCER CENTER   (China)

Author keywords

[No Author keywords available]

Indexed keywords

AGAR; PHOSPHOLIPASE C; PHOSPHOLIPASE C DELTA1; PROTEIN KINASE B; PROTEIN P21; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CANCER INHIBITION; CARCINOGENESIS; CELL ADHESION; CELL CYCLE; CELL CYCLE G1 PHASE; CELL CYCLE S PHASE; CELL LINE; CELL MOTILITY; CONTROLLED STUDY; DOWN REGULATION; ESOPHAGEAL SQUAMOUS CELL CARCINOMA; GENE EXPRESSION; HUMAN; HUMAN CELL; HUMAN TISSUE; IN VITRO STUDY; IN VIVO STUDY; METASTASIS; MOUSE; NONHUMAN; PRIORITY JOURNAL; UPREGULATION;

ANIMALS; CARCINOMA, SQUAMOUS CELL; CELL LINE, TUMOR; CHROMOSOMES, HUMAN, PAIR 3; DISEASE PROGRESSION; DNA METHYLATION; ESOPHAGEAL NEOPLASMS; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; IN SITU HYBRIDIZATION, FLUORESCENCE; MICE; MICE, NUDE; NEOPLASM METASTASIS; NEOPLASM TRANSPLANTATION; PHOSPHOLIPASE C DELTA;

EID: 36349033101     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: 10.1158/0008-5472.CAN-07-2411     Document Type: Article

References (38)

1. Parkin DM, Bray FI, Devesa SS. Cancer burden in the year 2000. The global picture. Eur J Cancer 2001;37:S4-66.
2. Ke L. Mortality and incidence trends from esophagus cancer in selected geographic areas of China circa 1970-90. Int J Cancer 2002;102:271-4.
3. Pack SD, Karkera JD, Zhuang Z, et al. Molecular cytogenetic fingerprinting of esophageal squamous cell carcinoma by comparative genomic hybridization reveals a consistent pattern of chromosomal alterations. Genes Chromosomes Cancer 1999;25:160-8.
4. Yen CC, Chen YJ, Chen JT, et al. Comparative genomic hybridization of esophageal squamous cell carcinoma: correlations between chromosomal aberrations and disease progression/prognosis. Cancer 2001;92:2769-77.
5. Kwong D, Lam A, Guan X, et al. Chromosomal aberrations in esophageal squamous cell carcinoma among Chinese: gain of 12p predicts poor prognosis after surgery. Hum Pathol 2004;35:309-16.
6. Ogasawara S, Maesawa C, Tamura G, Satodate R. Frequent microsatellite alterations on chromosome 3p in esophageal squamous cell carcinoma. Cancer Res 1995;55:891-4.
7. Rhee SG, Bae YS. Regulation of phosphoinositide-specific phospholipase C isozymes. J Biol Chem 1997;272:15045-8.
8. Kelley GG, Reks SE, Ondrako JM, Smrcka AV. Phospholipase C(ε): a novel Ras effector. EMBO J 2001;20:743-54.
9. Berridge MJ, Irvine RF. Inositol trisphosphate, a novel second messenger in cellular signal transduction. Nature 1984;312:315-21.
10. Nishizuka Y. The molecular heterogeneity of protein kinase C and its implications for cellular regulation. Nature 1988;334:661-5.
11. Rebecchi MJ, Pentyala SN. Structure, function, and control of phosphoinositide-specific phospholipase C. Physiol Rev 2000;80:1291-35.
12. Ryu SH, Kim UH, Wahl MI, et al. Feedback regulation of phospholipase C-β by protein kinase C. J Biol Chem 1990;265:17941-5.
13. Shimada Y, Imamura M, Wagata T, Yamaguchi N, Tobe T. Characterization of 21 newly established esophageal cancer cell lines. Cancer 1992;69:277-84.
14. Tao Q, Huang H, Geiman TM, et al. Defective de novo methylation of viral and cellular DNA sequences in ICF syndrome cells. Hum Mol Genet 2002;11:2091-102.
15. Guan XY, Sham JST, Tang TCM, Fang Y, Huo KK, Yang JM. Isolation of a novel candidate oncogene within a frequently amplified region at 3q26 in ovarian cancer. Cancer Res 2001;61:3806-9.
16. Xie D, Sham JS, Zeng WF, et al. Heterogeneous expression and association of β-catenin, p16 and c-myc in multistage colorectal tumorigenesis and progression detected by tissue microarray. Int J Cancer 2003;107:896-902.
17. Cao ZA, Daniel D, Hanahan D. Sub-lethal radiation enhances anti-tumor immunotherapy in a transgenic mouse model of pancreatic cancer. BMC Cancer 2002;3:2-11.
18. Knudson AG, Jr. Hereditary cancer, oncogenes, and antioncogenes. Cancer Res 1985;45:1437-43.
19. Ohta M, Inoue H, Cotticelli MG, et al. The FHIT gene, spanning the chromosome 3p14.2 fragile site and renal carcinoma-associated t(3;8) breakpoint, is abnormal in digestive tract cancers. Cell 1996;84:587-97.
20. Dammann R, Li C, Yoon JH, Chin PL, Bates S, Pfeifer GP. Epigenetic inactivation of a RAS association domain family protein from the lung tumor suppressor locus 3p21.3. Nat Genet 2000;25:315-9.
21. Ji L, Nishizaki M, Gao B, et al. Expression of several genes in the human chromosome 3p21.3 homozygous deletion region by an adenovirus vector results in tumor suppressor activities in vitro and in vivo. Cancer Res 2002;62:2715-20.
22. Daigo Y, Nishiwaki T, Kawasoe T, Tamari M, Tsuchiya E, Nakamura Y. Molecular cloning of a candidate tumor suppressor gene, DLC1, from chromosome 3p21.3. Cancer Res 1999;59:1966-72.
23. Ko JM, Wong CP, Tang CM, Lau KW, Lung ML. Frequent loss of heterozygosity on multiple chromosomes in Chinese esophageal squamous cell carcinomas. Cancer Lett 2001;170:131-8.
24. Shiomi H, Sugihara H, Kamitani S, et al. Cytogenetic heterogeneity and progression of esophageal squamous cell carcinoma. Cancer Genet Cytogenet 2003;147:50-61.
25. Kuroki T, Trapasso F, Yendamuri S, et al. Allele loss and promoter hypermethylation of VHL, RAR-β, RASSF1A, and FHIT tumor suppressor genes on chromosome 3p in esophageal squamous cell carcinoma. Cancer Res 2003;63:3724-8.
26. Lo PH, Leung AC, Kwok CY, et al. Identification of a tumor suppressive critical region mapping to 3p14.2 in esophageal squamous cell carcinoma and studies of a candidate tumor suppressor gene, ADAMTS9. Oncogene 2007;26:148-57.
27. Homma Y, Emori Y. A dual functional signal mediator showing RhoGAP and phospholipase C-δ stimulating activities. EMBO J 1995;14:286-91.
28. Yuan BZ, Miller MJ, Keck CL, Zimonjic DB, Thorgeirsson SS, Popescu NC. Cloning, characterization, and chromosomal localization of a gene frequently deleted in human liver cancer (DLC-1) homologous to rat RhoGAP. Cancer Res 1998;58:2196-9.
29. Ng IO, Liang ZD, Cao L, Lee TK. DLC-1 is deleted in primary hepatocellular carcinoma and exerts inhibitory effects on the proliferation of hepatoma cell lines with deleted DLC-1. Cancer Res 2000;60:6581-4.
30. Yuan BZ, Durkin ME, Popescu NC. Promoter hypermethylation of DLC-1, a candidate tumor suppressor gene, in several common human cancers. Cancer Genet Cytogenet 2003;140:113-7.
31. Wong CM, Lee JM, Ching YP, Jin DY, Ng IO. Genetic and epigenetic alterations of DLC-1 gene in hepatocellular carcinoma. Cancer Res 2003;63:7646-51.
32. Ullmannova V, Popescu NC. Inhibition of cell proliferation, induction of apoptosis, reactivation of DLC1, and modulation of other gene expression by dietary flavone in breast cancer cell lines. Cancer Detect Prev 2007;31:110-8.
33. Carnero A, Hannon GJ. The INK4 family of CDK inhibitors. Curr Top Microbiol Immunol 1998;227:43-55.
34. Sechi AS, Wehland J. The actin cytoskeleton and plasma membrane connection: PtdIns(4,5)P(2) influences cytoskeletal protein activity at the plasma membrane. J Cell Sci 2000;113:3685-95.
35. Kawai K, Yamaga M, Iwamae Y, et al. A PLCδ1-binding protein, p122RhoGAP, is localized in focal adhesions. Biochem Soc Trans 2004;32:1107-9.
36. Kim TY, Lee JW, Kim HP, et al. DLC-1, a GTPase-activating protein for Rho, is associated with cell proliferation, morphology, and migration in human hepatocellular carcinoma. Biochem Biophys Res Commun 2007;355:72-7.
37. Rossig L, Jadidi AS, Urbich C, Badorff C, Zeiher AM, Dimmeler S. AKT-dependent phosphorelation of p21(Cip1) regulates PCNA binding and proliferation of endothelial cells. Mol Cell Biol 2001;21:5644-57.
38. Zhou BP, Liao Y, Xia W, Spohn B, Lee MH, Hung MC. Cytoplasmic localization of p21Cip1/WAF1 by Akt-induced phosphorylation in HER-2/neu-overexpressing cells. Nat Cell Biol 2001;3:245-52.